SI2090657T1 - Anti-IL-12 protitelesa, sestavki, postopki in uporabe - Google Patents
Anti-IL-12 protitelesa, sestavki, postopki in uporabeInfo
- Publication number
- SI2090657T1 SI2090657T1 SI200131060A SI200131060A SI2090657T1 SI 2090657 T1 SI2090657 T1 SI 2090657T1 SI 200131060 A SI200131060 A SI 200131060A SI 200131060 A SI200131060 A SI 200131060A SI 2090657 T1 SI2090657 T1 SI 2090657T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibodies
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22335800P | 2000-08-07 | 2000-08-07 | |
US23682700P | 2000-09-29 | 2000-09-29 | |
US09/920,262 US6902734B2 (en) | 2000-08-07 | 2001-08-01 | Anti-IL-12 antibodies and compositions thereof |
EP09006396.7A EP2090657B1 (en) | 2000-08-07 | 2001-08-07 | Anti-IL-12 antibodies, compositions, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2090657T1 true SI2090657T1 (sl) | 2017-06-30 |
Family
ID=27397221
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200131070T SI3178934T1 (sl) | 2000-08-07 | 2001-08-07 | Protitelesa proti-IL-12, sestavki, postopki in uporabe za zdravljenje Crohnove patologije |
SI200130913T SI1309692T1 (sl) | 2000-08-07 | 2001-08-07 | Anti-il-12 protitelesa, sestavki, postopki in uporabe |
SI200131066T SI2305817T1 (sl) | 2000-08-07 | 2001-08-07 | Anti-IL-12 protitelesa, sestavki, postopki in uporabe |
SI200131060A SI2090657T1 (sl) | 2000-08-07 | 2001-08-07 | Anti-IL-12 protitelesa, sestavki, postopki in uporabe |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200131070T SI3178934T1 (sl) | 2000-08-07 | 2001-08-07 | Protitelesa proti-IL-12, sestavki, postopki in uporabe za zdravljenje Crohnove patologije |
SI200130913T SI1309692T1 (sl) | 2000-08-07 | 2001-08-07 | Anti-il-12 protitelesa, sestavki, postopki in uporabe |
SI200131066T SI2305817T1 (sl) | 2000-08-07 | 2001-08-07 | Anti-IL-12 protitelesa, sestavki, postopki in uporabe |
Country Status (33)
Country | Link |
---|---|
US (15) | US6902734B2 (sl) |
EP (5) | EP1309692B1 (sl) |
JP (4) | JP4731094B2 (sl) |
KR (1) | KR100823576B1 (sl) |
CN (2) | CN1468309A (sl) |
AR (1) | AR030134A1 (sl) |
AT (1) | ATE431412T1 (sl) |
AU (2) | AU8113701A (sl) |
BR (1) | BRPI0113109B8 (sl) |
CA (1) | CA2418961C (sl) |
CL (1) | CL2009000575A1 (sl) |
CY (7) | CY1109149T1 (sl) |
DE (2) | DE60138711D1 (sl) |
DK (4) | DK2305817T3 (sl) |
EA (1) | EA006673B1 (sl) |
ES (4) | ES2323760T3 (sl) |
FR (1) | FR09C0021I2 (sl) |
HK (1) | HK1135991A1 (sl) |
HR (1) | HRP20030087B1 (sl) |
HU (1) | HU228009B1 (sl) |
IL (1) | IL154325A (sl) |
LT (6) | LT3178934T (sl) |
LU (3) | LU91584I2 (sl) |
ME (1) | ME00326B (sl) |
MX (1) | MXPA03001229A (sl) |
MY (1) | MY133377A (sl) |
NL (1) | NL300390I2 (sl) |
NO (3) | NO330903B1 (sl) |
NZ (2) | NZ535865A (sl) |
PT (4) | PT3178934T (sl) |
RS (1) | RS50477B (sl) |
SI (4) | SI3178934T1 (sl) |
WO (1) | WO2002012500A2 (sl) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6706264B1 (en) * | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
AU2003218432A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
WO2003082206A2 (en) * | 2002-03-26 | 2003-10-09 | Centocor, Inc. | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
CN101824088B (zh) | 2002-10-30 | 2012-05-30 | 健泰科生物技术公司 | Il-17产生的抑制 |
EP2390268B1 (en) * | 2002-11-08 | 2017-11-01 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
ES2655912T3 (es) * | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
NZ544797A (en) * | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
NZ548897A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Methods of modulating IL-23 activity; related reagents |
US7736650B2 (en) * | 2004-12-21 | 2010-06-15 | Centocor, Inc. | Anti-IL-12 antibody based vectors, host cells, and methods of production and uses |
CN101120087A (zh) | 2004-12-21 | 2008-02-06 | 森托科尔公司 | 抗-il-12抗体、表位、组合物、方法和用途 |
EP1871803B1 (en) | 2005-04-18 | 2013-02-20 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis b (hbv) antibody formulations |
MX2007016401A (es) * | 2005-06-30 | 2008-02-20 | Abbott Lab | Proteinas de union il-12/p40. |
JP2007172129A (ja) * | 2005-12-20 | 2007-07-05 | Sony Corp | 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム |
AU2007266306A1 (en) * | 2006-05-26 | 2007-12-06 | Apollo Life Sciences Limited | An isolated IL-12 molecule or chimeric molecules thereof |
WO2008070647A1 (en) * | 2006-12-07 | 2008-06-12 | Wyeth | Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample |
AU2008205512B2 (en) * | 2007-01-16 | 2014-06-12 | Abbvie Inc. | Methods for treating psoriasis |
CN101679507A (zh) * | 2007-03-29 | 2010-03-24 | 艾博特公司 | 结晶抗人类il-12抗体 |
EP2205276A4 (en) * | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
WO2009117289A2 (en) | 2008-03-18 | 2009-09-24 | Abbott Laboratories | Methods for treating psoriasis |
KR20110025649A (ko) | 2008-05-05 | 2011-03-10 | 노비뮨 에스 에이 | 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법 |
AU2009307737B2 (en) * | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
CN102257004A (zh) * | 2008-10-20 | 2011-11-23 | 雅培制药有限公司 | 与il-12结合的抗体及其纯化方法 |
EP2350649A4 (en) * | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
RU2605318C2 (ru) | 2009-05-05 | 2016-12-20 | Новиммун С.А. | Анти-il-17f антитела и способы их применения |
RU2012114854A (ru) * | 2009-09-14 | 2013-10-27 | Эбботт Лэборетриз | Способы лечения псориаза |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
TW201309330A (zh) * | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
US9580501B2 (en) | 2011-12-16 | 2017-02-28 | Synthon Biopharmaceuticals B.V. | Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases |
EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
MX2019001355A (es) | 2012-05-10 | 2023-01-17 | Bioatla Llc | Anticuerpos monoclonales multiespecíficos. |
ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
CN107614012A (zh) * | 2015-04-24 | 2018-01-19 | 加利福尼亚大学董事会 | 使用工程化的细胞检测、监测或治疗疾病或病况的***及制备和使用它们的方法 |
TW201722989A (zh) * | 2015-10-23 | 2017-07-01 | 輝瑞大藥廠 | 抗il-2抗體及其組合物及用途 |
EA201892190A1 (ru) * | 2016-03-29 | 2019-04-30 | Янссен Байотек, Инк. | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы |
US20200347126A1 (en) | 2016-08-03 | 2020-11-05 | Fyb 202 Project Gmbh | Production of Biosimilar Ustekinumab In CHO Cells |
MA46861A (fr) * | 2016-11-16 | 2019-09-25 | Janssen Biotech Inc | Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CN110072551B (zh) | 2016-12-14 | 2023-05-23 | 比奥拉治疗股份有限公司 | 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病 |
MX2019008989A (es) | 2017-01-30 | 2019-10-09 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. |
MX2019009377A (es) | 2017-02-07 | 2019-12-11 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa. |
EP3635093A1 (en) | 2017-06-08 | 2020-04-15 | Polpharma Biologics S.A. | Improved methods of cell culture |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019106206A1 (en) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
JP7421500B2 (ja) | 2018-05-18 | 2024-01-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体でループスを治療する安全かつ有効な方法 |
TR201808283A2 (tr) * | 2018-06-11 | 2018-07-23 | Centurion Ilac San Ve Tic A S | Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ |
WO2019246271A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20200061015A1 (en) | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
US10961307B2 (en) | 2018-09-24 | 2021-03-30 | Janssen Biotech, Inc. | Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
AU2019383017A1 (en) | 2018-11-20 | 2021-06-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
CN113574066A (zh) | 2019-01-15 | 2021-10-29 | 詹森生物科技公司 | 用于治疗幼年特发性关节炎的抗tnf抗体组合物和方法 |
EA202192038A1 (ru) | 2019-01-23 | 2021-10-05 | Янссен Байотек, Инк. | Композиции антител к фно для применения в способах лечения псориатического артрита |
JP2022524860A (ja) | 2019-03-14 | 2022-05-10 | ヤンセン バイオテツク,インコーポレーテツド | 抗tnf抗体組成物を産生するための方法 |
US20220144934A1 (en) | 2019-03-14 | 2022-05-12 | Janssen Biotech, Inc. | Methods for Producing Anti-TNF Antibody Compositions |
US20220153830A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
MA55383A (fr) * | 2019-03-18 | 2022-01-26 | Janssen Biotech Inc | Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23 |
CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
WO2020245677A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
CA3142665A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
EP4008727A4 (en) * | 2019-07-30 | 2024-01-17 | Akeso Biopharma Inc | HUMANIZED ANTIBODY DIRECTED AGAINST THE P40 PROTEIN DOMAIN AND ITS USE |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US11396541B2 (en) | 2019-12-20 | 2022-07-26 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 P19 antibodies and methods of use thereof |
EP4188443A1 (en) * | 2020-07-30 | 2023-06-07 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
KR20240032991A (ko) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물의 생성을 위한 제조 방법 |
KR20240034218A (ko) | 2021-07-09 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물을 생산하기 위한 제조 방법 |
WO2023166420A1 (en) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122464A (en) | 1872-01-02 | Improvement in cheese-hoops | ||
US941234A (en) | 1909-02-25 | 1909-11-23 | Frank De Clercq | Syrup-percolator. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
DE3546806C2 (sl) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
GB8517895D0 (en) | 1985-07-16 | 1985-08-21 | Technology Licence Co Ltd | Monoclonal antibodies |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
EP0396612B1 (en) | 1988-01-11 | 1996-07-24 | Xoma Corporation | Novel plasmid vector with pectate lyase signal sequence |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
AU638430B2 (en) | 1988-11-10 | 1993-07-01 | Genetics Institute, Llc | Natural killer stimulatory factor |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
DE69027121T3 (de) | 1989-08-07 | 2001-08-30 | Peptech Ltd | Bindeligande für tumornekrosisfaktor |
ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69034249T2 (de) | 1989-12-22 | 2008-05-29 | F. Hoffmann-La Roche Ag | Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor |
US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
TW212184B (sl) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU8081491A (en) | 1990-06-01 | 1991-12-31 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
EP0592540B1 (en) | 1991-07-02 | 2000-01-26 | Inhale, Inc. | Method and device for delivering aerosolized medicaments |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
WO1994008038A1 (en) | 1992-10-02 | 1994-04-14 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
SK279327B6 (sk) | 1992-10-19 | 1998-10-07 | Dura Pharmaceuticals | Zariadenie na vytváranie aerosolu z práškového lie |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
US5300478A (en) * | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
PL310327A1 (en) | 1993-02-12 | 1995-12-11 | Univ Leland Stanford Junior | Adjustable transcription of target genes and other biological processes |
US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
EP0614989A1 (en) | 1993-02-17 | 1994-09-14 | MorphoSys AG | A method for in vivo selection of ligand-binding proteins |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
KR950701934A (ko) * | 1993-04-30 | 1995-05-17 | 아사이 잇뻬이 | 소수성 폴리펩티드의 정제방법(purification method for hydrophobic polypeptide) |
DE4315127A1 (de) | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AU692239B2 (en) | 1994-03-07 | 1998-06-04 | Medarex, Inc. | Bispecific molecules having clinical utilities |
ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
BR9507505A (pt) | 1994-04-22 | 1997-09-02 | Corixa Corp | Molécula de dna isolada vetor de expressão recombinante célula hospedeira método para preparar um polipeptídeo que estimula uma resposta imunológica th1 em células mononucleares do sangue periférico obtidas a partir de um individuo infectado com leishmania polipeptídeo método para avaliar a capacidade de um paciente de gerar uma resposta imunológica método para melhorar uma resposta imunológica celular e/ou humoral a um antígeno de um paciente método para estimular a produção de anticorpos em um |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
ATE390933T1 (de) * | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
AP9801285A0 (en) | 1996-01-03 | 1998-09-30 | Glaxo Group Ltd | Inhalation device. |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
ES2169299T3 (es) | 1996-09-03 | 2002-07-01 | Gsf Forschungszentrum Umwelt | Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos. |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
AU6150498A (en) | 1997-02-07 | 1998-08-26 | Wistar Institute, The | Methods and compositions for the inhibition of interleukin-12 production |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
CA2318052C (en) | 1998-01-23 | 2012-07-03 | F. Hoffmann-La Roche Ag | Antibodies against human il-12 |
CA2353520C (en) | 1998-12-09 | 2006-04-25 | Protein Design Labs, Inc. | Animal model for psoriasis for the prevention and treatment of psoriasis in humans |
NZ592550A (en) * | 1999-03-25 | 2012-12-21 | Abbott Gmbh & Co Kg | Compostion comprising antibody capable of binding to p40 subunit of IL-12 |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
AU7127600A (en) | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
AU2003247411A1 (en) | 2002-05-23 | 2003-12-12 | Cognis Corporation | NON-REVERTIBLE Beta-OXIDATION BLOCKED CANDIDA TROPICALIS |
DE102007030072A1 (de) | 2007-06-29 | 2009-01-02 | BSH Bosch und Siemens Hausgeräte GmbH | Elektrischen Antriebseinrichtung für ein Wasserführendes Haushaltsgerät |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP5155355B2 (ja) | 2010-04-07 | 2013-03-06 | レノボ・シンガポール・プライベート・リミテッド | 無線基地局の自律的な負荷調整が可能な無線端末装置 |
US9619256B1 (en) | 2012-06-27 | 2017-04-11 | EMC IP Holding Company LLC | Multi site and multi tenancy |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9205258B2 (en) | 2013-11-04 | 2015-12-08 | ElectroCore, LLC | Nerve stimulator system |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2001
- 2001-08-01 US US09/920,262 patent/US6902734B2/en not_active Expired - Lifetime
- 2001-08-07 AT AT01959598T patent/ATE431412T1/de active
- 2001-08-07 SI SI200131070T patent/SI3178934T1/sl unknown
- 2001-08-07 PT PT171533367T patent/PT3178934T/pt unknown
- 2001-08-07 AU AU8113701A patent/AU8113701A/xx active Pending
- 2001-08-07 EP EP01959598A patent/EP1309692B1/en not_active Expired - Lifetime
- 2001-08-07 ES ES01959598T patent/ES2323760T3/es not_active Expired - Lifetime
- 2001-08-07 EA EA200300137A patent/EA006673B1/ru not_active IP Right Cessation
- 2001-08-07 MX MXPA03001229A patent/MXPA03001229A/es active IP Right Grant
- 2001-08-07 NZ NZ535865A patent/NZ535865A/en not_active IP Right Cessation
- 2001-08-07 ES ES17153336T patent/ES2747573T3/es not_active Expired - Lifetime
- 2001-08-07 PT PT01959598T patent/PT1309692E/pt unknown
- 2001-08-07 LT LTEP17153336.7T patent/LT3178934T/lt unknown
- 2001-08-07 WO PCT/US2001/024720 patent/WO2002012500A2/en active IP Right Grant
- 2001-08-07 CN CNA018169619A patent/CN1468309A/zh active Pending
- 2001-08-07 ES ES10184116.1T patent/ES2647220T3/es not_active Expired - Lifetime
- 2001-08-07 JP JP2002517788A patent/JP4731094B2/ja not_active Expired - Lifetime
- 2001-08-07 LT LTEP10184116.1T patent/LT2305817T/lt unknown
- 2001-08-07 SI SI200130913T patent/SI1309692T1/sl unknown
- 2001-08-07 DK DK10184116.1T patent/DK2305817T3/en active
- 2001-08-07 PT PT101841161T patent/PT2305817T/pt unknown
- 2001-08-07 DK DK01959598T patent/DK1309692T3/da active
- 2001-08-07 SI SI200131066T patent/SI2305817T1/sl unknown
- 2001-08-07 EP EP10184116.1A patent/EP2305817B1/en not_active Expired - Lifetime
- 2001-08-07 ES ES09006396.7T patent/ES2624502T3/es not_active Expired - Lifetime
- 2001-08-07 IL IL154325A patent/IL154325A/en active Protection Beyond IP Right Term
- 2001-08-07 RS YUP-93/03A patent/RS50477B/sr unknown
- 2001-08-07 DK DK17153336.7T patent/DK3178934T3/da active
- 2001-08-07 EP EP09006396.7A patent/EP2090657B1/en not_active Expired - Lifetime
- 2001-08-07 EP EP17153336.7A patent/EP3178934B1/en not_active Expired - Lifetime
- 2001-08-07 NZ NZ524145A patent/NZ524145A/en not_active IP Right Cessation
- 2001-08-07 SI SI200131060A patent/SI2090657T1/sl unknown
- 2001-08-07 PT PT90063967T patent/PT2090657T/pt unknown
- 2001-08-07 KR KR1020037001843A patent/KR100823576B1/ko active Protection Beyond IP Right Term
- 2001-08-07 LT LTEP09006396.7T patent/LT2090657T/lt unknown
- 2001-08-07 CN CN200810100025.3A patent/CN101550190B/zh not_active Expired - Lifetime
- 2001-08-07 DK DK09006396.7T patent/DK2090657T3/en active
- 2001-08-07 BR BRPI0113109A patent/BRPI0113109B8/pt active IP Right Grant
- 2001-08-07 EP EP19179253.0A patent/EP3597752A1/en not_active Withdrawn
- 2001-08-07 ME MEP-2008-444A patent/ME00326B/me unknown
- 2001-08-07 AR ARP010103780A patent/AR030134A1/es active IP Right Grant
- 2001-08-07 CA CA002418961A patent/CA2418961C/en not_active Expired - Lifetime
- 2001-08-07 DE DE60138711T patent/DE60138711D1/de not_active Expired - Lifetime
- 2001-08-07 AU AU2001281137A patent/AU2001281137B2/en active Active
- 2001-08-07 DE DE122009000025C patent/DE122009000025I1/de active Pending
- 2001-08-07 MY MYPI20013706 patent/MY133377A/en unknown
- 2001-08-07 HU HU0302378A patent/HU228009B1/hu active Protection Beyond IP Right Term
-
2003
- 2003-02-07 NO NO20030614A patent/NO330903B1/no not_active IP Right Cessation
- 2003-02-07 HR HRP20030087AA patent/HRP20030087B1/xx not_active IP Right Cessation
-
2004
- 2004-08-06 US US10/912,994 patent/US20050002937A1/en not_active Abandoned
- 2004-10-28 US US10/975,708 patent/US7166285B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,740 patent/US7063964B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,883 patent/US7279157B2/en not_active Expired - Lifetime
-
2007
- 2007-01-29 US US11/668,256 patent/US7560247B2/en not_active Expired - Lifetime
-
2009
- 2009-03-11 CL CL2009000575A patent/CL2009000575A1/es unknown
- 2009-05-13 NL NL300390C patent/NL300390I2/nl unknown
- 2009-05-13 FR FR09C0021C patent/FR09C0021I2/fr active Active
- 2009-05-15 LT LTPA2009002C patent/LTC1309692I2/lt unknown
- 2009-06-09 CY CY20091100601T patent/CY1109149T1/el unknown
- 2009-06-12 CY CY2009007C patent/CY2009007I1/el unknown
- 2009-07-09 US US12/500,120 patent/US7887807B2/en not_active Expired - Fee Related
- 2009-07-10 LU LU91584C patent/LU91584I2/fr unknown
-
2010
- 2010-01-05 HK HK10100042.6A patent/HK1135991A1/zh not_active IP Right Cessation
- 2010-12-17 US US12/971,626 patent/US8084233B2/en not_active Expired - Fee Related
-
2011
- 2011-03-10 JP JP2011052971A patent/JP2011173884A/ja not_active Withdrawn
- 2011-10-04 NO NO2011023C patent/NO2011023I1/no not_active IP Right Cessation
- 2011-10-26 JP JP2011235204A patent/JP2012025779A/ja active Pending
- 2011-11-18 US US13/299,874 patent/US8329171B2/en not_active Expired - Lifetime
-
2012
- 2012-11-07 US US13/670,918 patent/US8703141B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 US US14/190,893 patent/US9409984B2/en not_active Expired - Lifetime
- 2014-09-22 JP JP2014192690A patent/JP6076303B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-30 US US15/198,678 patent/US9676848B2/en not_active Expired - Lifetime
-
2017
- 2017-05-01 US US15/583,487 patent/US10259867B2/en not_active Expired - Fee Related
- 2017-05-18 CY CY20171100525T patent/CY1118901T1/el unknown
- 2017-12-05 CY CY20171101269T patent/CY1119650T1/el unknown
-
2018
- 2018-03-19 CY CY2018010C patent/CY2018010I2/el unknown
- 2018-03-20 LU LU00066C patent/LUC00066I2/fr unknown
- 2018-03-20 LT LTPA2018007C patent/LTC2305817I2/lt unknown
-
2019
- 2019-02-25 US US16/284,316 patent/US10519231B2/en not_active Expired - Fee Related
- 2019-10-02 CY CY20191101021T patent/CY1122505T1/el unknown
- 2019-11-07 US US16/677,120 patent/US11078267B2/en not_active Expired - Lifetime
-
2020
- 2020-01-10 LU LU00145C patent/LUC00145I2/fr unknown
- 2020-01-13 LT LTPA2020001C patent/LTPA2020001I1/lt unknown
- 2020-01-16 CY CY2020003C patent/CY2020003I1/el unknown
- 2020-03-11 NO NO2020005C patent/NO2020005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300390I2 (en) | Anti-IL-12 antibodies, compositions, methods and uses | |
HUP0302376A3 (en) | Anti-tnf antibodies, compositions, methods and uses | |
HK1083509A1 (en) | Anti-il-6 antibodies, compositions, methods and uses | |
HUP0302128A3 (en) | Anti-dual integrin antibodies, compositions, methods and uses | |
EP1578930A4 (en) | CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES | |
AU2002359495A8 (en) | Anti-tnf antibodies, compositions, methods and uses | |
IL161235A0 (en) | Fsh composition, its preparation and use | |
EP1711527A4 (en) | HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS | |
EP1539792A4 (en) | CNGH0005 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES | |
AU2002365269A8 (en) | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses | |
AU2003237332A8 (en) | Anti-relp fusion antibodies, compositions, methods and uses | |
EP1277459A4 (en) | PERMANENT SHAFT MEANS AND METHOD FOR PERMANENT SHAFT USING THIS | |
EP1501870A4 (en) | RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES | |
GB0128964D0 (en) | Assays, methods and means | |
GB0010191D0 (en) | Assays, methods and means | |
GB0031284D0 (en) | High affinity antibodies | |
GB0123388D0 (en) | Assays,methods and means | |
GB0111574D0 (en) | Assays,methods and means | |
GB0118952D0 (en) | Assays,methods and means | |
GB0003527D0 (en) | Antibodies |